Armata Pharmaceuticals Inc (A:ARMP)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 4503 Glencoe Ave
MARINA DEL REY CA 90292-6372
Tel: N/A
Website: https://www.armatapharma.com
IR: See website
<
Key People
Jeremy Laurence Curnock-Cook
Chairman of the Board
Brian Varnum
President, Chief Development Officer
Todd R. Patrick
Chief Executive Officer, Director
Steven Robert Martin
Chief Financial Officer
Igor P. Bilinsky
Chief Operating Officer, Senior Vice President
Duane Alfred Morris
Vice President - Operations
Mina Pastagia
Vice President - Clinical Development
Heather Jones
Medical Director
 
Business Overview
Armata Pharmaceuticals, Inc., formerly AmpliPhi Biosciences Corporation, is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products. The Company is engaged in developing these phage product candidates using a discovery and development platform, which is designed for identification, characterization and manufacturing of multiple phage therapies. Each product candidate combines several chosen phages, which target a specific disease-causing bacterial pathogen, such as staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa) and clostridium difficile (C. difficile). Its product candidates are AB-SA01 and AB-PA01.
Financial Overview
For the six months ended 30 June 2020, ArmataPharmaceuticals Inc revenues increased from $0K to $31K.Net loss increased 23% to $9.8M. Revenues reflect anincrease in demand for the Company's products and servicesdue to favorable market conditions. Higher net lossreflects Change in fair value of derivative liabi decreasefrom $1.1M (income) to $0K, Stock-based Compensation in SGAincrease from $474K to $1.3M (expense).
Employees: 33 as of Mar 6, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $40.86M as of Jun 30, 2020
Annual revenue (TTM): $0.03M as of Jun 30, 2020
EBITDA (TTM): -$17.61M as of Jun 30, 2020
Net annual income (TTM): -$21.33M as of Jun 30, 2020
Free cash flow (TTM): -$15.72M as of Jun 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 18,668,883 as of Aug 12, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.